Editorials Treating Shiga toxin induced haemolytic uraemic syndrome BMJ 2012; 345 doi: https://doi.org/10.1136/bmj.e4598 (Published 19 July 2012) Cite this as: BMJ 2012;345:e4598 Article Related content Metrics Responses Peer review Related articles Research Validation of treatment strategies for enterohaemorrhagic Escherichia coli O104:H4 induced haemolytic uraemic syndrome: case-control study Published: 19 July 2012; BMJ 345 doi:10.1136/bmj.e4565 ResearchValidation of treatment strategies for enterohaemorrhagic Escherichia coli O104:H4 induced haemolytic uraemic syndrome: case-control study See more Johnson & Johnson is ordered to pay $1bn over faulty hip implants BMJ December 06, 2016, 355 i6551; DOI: https://doi.org/10.1136/bmj.i6551 Trial of novel leukaemia drug is stopped for second time after two more deaths BMJ November 25, 2016, 355 i6376; DOI: https://doi.org/10.1136/bmj.i6376 A question of evidence BMJ November 24, 2016, 355 i6316; DOI: https://doi.org/10.1136/bmj.i6316 A national prescription drug line could help to assess the non-medical use of prescription drugs BMJ November 16, 2016, 355 i6084; DOI: https://doi.org/10.1136/bmj.i6084 Spice and all things nasty: the challenge of synthetic cannabinoids BMJ October 24, 2016, 355 i5639; DOI: https://doi.org/10.1136/bmj.i5639 Cited by... Microbes without frontiers: severe haemolytic-uraemic syndrome due to E coli O104:H4Abstract Fulltext PDF
